Understanding Aldosterone Signaling in Heart Failure
This study aims to understand how the body responds to aldosterone, a hormone, in people with heart failure, especially when taking standard medications like spironolactone. Researchers are testing different combinations of an IV (intravenous) infusion of aldosterone or a vehicle (inactive substance) along with an oral placebo pill or 25mg spironolactone. You could be eligible if you have stable heart failure (NYHA class I or II), good kidney function (eGFR > 30), and stable potassium levels. The study will measure changes in your urine sodium to potassium ratio to see how well these treatments work. The current recruitment status is unclear, and they plan to enroll 20 participants.
- Study design
- This is a randomized, double-blind, double-dummy, placebo-controlled, crossover study involving 20 participants. This means participants will receive different treatments in a random order, and neither you nor the study team will know which treatment you are receiving at any given time.
- What's involved
- Participants will receive four different treatment combinations, each separated by two weeks. This involves IV infusions, oral pills, and collecting biospecimens.
- Compensation
- Not stated in the trial record.
- Follow-up
- The primary endpoint, change in urine sodium to potassium ratio, is measured at 59 days.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
Unmitigated Aldosterone Signaling During Standard Clinical MRA Dosing
At a glance
Conditions
NCT07281014
Where you'd take part
This study runs at 1 site. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.
Yale University
New Haven, Connecticutno site contact published
Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.
Study leadership
- Jeffrey Testani, MD · PRINCIPAL_INVESTIGATOR · Yale University
Who to contact
This trial hasn't published a contact. View it on ClinicalTrials.gov
Want this trial checked against your situation?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Exclusion
What this trial measures
- change in urine sodium to potassium ratio59 days
Change in sodium to potassium ratio between aldosterone vs vehicle infusion during the spironolactone vs. placebo arms.